Literature DB >> 20826838

Targeting a common collaborator in cancer development.

Andrea P Myers1, Lewis C Cantley.   

Abstract

In this issue of Science Translational Medicine, Wallin et al. have identified a subset of breast and ovarian cancer cell lines that show synergistic response to the combination of doxorubicin and GDC-0941, a class IA phosphatidylinositol 3-kinase (PI3K) inhibitor. Here, we discuss the potential implications of these data on the clinical development of PI3K pathway inhibitors as cancer therapeutics.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20826838      PMCID： PMC3425950          DOI： 10.1126/scitranslmed.3001251

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  23 in total

1.  High frequency of mutations of the PIK3CA gene in human cancers.

Authors:  Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-03-11       Impact factor: 47.728

Review 2.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Authors:  Jeffrey A Engelman; Ji Luo; Lewis C Cantley
Journal:  Nat Rev Genet       Date:  2006-08       Impact factor: 53.242

Review 3.  Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.

Authors:  N Lynn Henry; Daniel F Hayes
Journal:  Oncologist       Date:  2006-06

4.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Authors:  J Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; N T Sklarin; A D Seidman; C A Hudis; J Moore; P P Rosen; T Twaddell; I C Henderson; L Norton
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

5.  Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.

Authors:  Robert D Mass; Michael F Press; Steven Anderson; Melody A Cobleigh; Charles L Vogel; Noël Dybdal; Grazyna Leiberman; Dennis J Slamon
Journal:  Clin Breast Cancer       Date:  2005-08       Impact factor: 3.225

6.  Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K.

Authors:  M Sun; J E Paciga; R I Feldman; Z Yuan ; D Coppola; Y Y Lu; S A Shelley; S V Nicosia; J Q Cheng
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

7.  Mutation of the PIK3CA gene in ovarian and breast cancer.

Authors:  Ian G Campbell; Sarah E Russell; David Y H Choong; Karen G Montgomery; Marianne L Ciavarella; Christine S F Hooi; Briony E Cristiano; Richard B Pearson; Wayne A Phillips
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

8.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

9.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

10.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Authors:  M D Pegram; A Lipton; D F Hayes; B L Weber; J M Baselga; D Tripathy; D Baly; S A Baughman; T Twaddell; J A Glaspy; D J Slamon
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544
View more
  15 in total

1.  Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome.

Authors:  Angelica A Saetta; Georgia Levidou; Elias A El-Habr; Ioannis Panayotidis; Vassilis Samaras; Irene Thymara; Stratigoula Sakellariou; Efstathios Boviatsis; Efstratios Patsouris; Penelope Korkolopoulou
Journal:  Virchows Arch       Date:  2011-04-15       Impact factor: 4.064

Review 2.  Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.

Authors:  Siver Andreas Moestue; Olav Engebraaten; Ingrid Susann Gribbestad
Journal:  Mol Oncol       Date:  2011-04-23       Impact factor: 6.603

3.  Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity.

Authors:  David E Durrant; Anindita Das; Samya Dyer; Seyedmehrad Tavallai; Paul Dent; Rakesh C Kukreja
Journal:  Mol Pharmacol       Date:  2015-06-22       Impact factor: 4.436

4.  DNA damage triggers Golgi dispersal via DNA-PK and GOLPH3.

Authors:  Suzette E Farber-Katz; Holly C Dippold; Matthew D Buschman; Marshall C Peterman; Mengke Xing; Christopher J Noakes; John Tat; Michelle M Ng; Juliati Rahajeng; David M Cowan; Greg J Fuchs; Huilin Zhou; Seth J Field
Journal:  Cell       Date:  2014-01-30       Impact factor: 41.582

5.  Contribution of xanthine oxidoreductase to mammary epithelial and breast cancer cell differentiation in part modulates inhibitor of differentiation-1.

Authors:  Mehdi A Fini; Jenifer Monks; Susan M Farabaugh; Richard M Wright
Journal:  Mol Cancer Res       Date:  2011-07-20       Impact factor: 5.852

6.  A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy.

Authors:  Nandini Dey; Jennifer Aske; Xiaoqian Lin; Yuliang Sun; Brian Leyland-Jones; Lori Friedman; Pradip De
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

7.  mTOR pathway: A current, up-to-date mini-review (Review).

Authors:  Paul Zarogoulidis; Sofia Lampaki; J Francis Turner; Haidong Huang; Stylianos Kakolyris; Konstantinos Syrigos; Konstantinos Zarogoulidis
Journal:  Oncol Lett       Date:  2014-10-10       Impact factor: 2.967

Review 8.  New insight for metformin against bladder cancer.

Authors:  Amr Ahmed El-Arabey
Journal:  Genes Environ       Date:  2017-04-01

9.  Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy.

Authors:  Avinash Das Sahu; Joo S Lee; Zhiyong Wang; Gao Zhang; Ramiro Iglesias-Bartolome; Tian Tian; Zhi Wei; Benchun Miao; Nishanth Ulhas Nair; Olga Ponomarova; Adam A Friedman; Arnaud Amzallag; Tabea Moll; Gyulnara Kasumova; Patricia Greninger; Regina K Egan; Leah J Damon; Dennie T Frederick; Livnat Jerby-Arnon; Allon Wagner; Kuoyuan Cheng; Seung Gu Park; Welles Robinson; Kevin Gardner; Genevieve Boland; Sridhar Hannenhalli; Meenhard Herlyn; Cyril Benes; Keith Flaherty; Ji Luo; J Silvio Gutkind; Eytan Ruppin
Journal:  Mol Syst Biol       Date:  2019-03-11       Impact factor: 11.429

Review 10.  Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia.

Authors:  Oro Uchenunu; Michael Pollak; Ivan Topisirovic; Laura Hulea
Journal:  J Mol Endocrinol       Date:  2019-02-01       Impact factor: 5.098
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.